s

Senzime reports from the American Society of Anesthesiologists (ASA)

For more than 67 years, the ASA Annual Meeting has been the most comprehensive anesthesia-related educational event in the world, bringing together top influential and notable professionals in anesthesiology, pain medicine and critical care medicine.

Numerous presenters discussed patient safety initiatives and necessary steps to reduce adverse events in the perioperative period. Professor Sorin J. Brull, MD from the Mayo Clinic and BOD member at Senzime, chaired a Session entitled, “Assessing and Analyzing the Perceptions of Perioperative Professionals on Neuromuscular Blockade Monitoring and Residual Neuromuscular Blockade.”

The session was supported by the Anesthesia Patient Safety Foundation (APSF) and the ASA, and aimed to identify the current practices of monitoring of patients for residual neuromuscular block, understand the perceptions of current practices, and determine the likely cause for inconsistent practice patterns among anesthesia professionals.  The ASA and APSF organizations will then develop a plan to address knowledge gaps that cause inconsistent practice patterns and misperceptions among anesthesia clinicians with regard to the monitoring of patients with residual neuromuscular block. The activities may then be reviewed by ASA in its deliberations on the creation of a guideline.  It is expected that the activity will inform the development of the ensuing phases of the patient safety initiative with a final result of procedural changes related to neuromuscular monitoring and management of neuromuscular blockade. 

 “The trend in anesthesia discussions today is all about having the patient in focus. Patients have the right to be safe and protected from harm while receiving medical care, and safe anesthesia is a key component,” says Lena Söderström, CEO of Senzime.

For further information, please contact: 

Lena Söderström, CEO

Tel: +46-708 16 39 12.  Email: lena.soderstrom@senzime.com

TO THE EDITORS  

About Senzime  

Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North (ticker SEZI). FNCA is Certified Adviser for Senzime. www.senzime.com